Cassava Sciences (SAVA)

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

O preço da ação Cassava Sciences, Inc. Common Stock (SAVA) pre-market hoje é de $ 2,24, refletindo uma movimentação de -3,86% pre-market desde que o mercado fechou. A capitalização de mercado da empresa é de $ 108,21 mi, com um volume comercial diário de $ 1,23 mil ações. O preço de fechamento anterior foi $ 2,33.

Vamos começar? Siga os passos abaixo ou leia nosso guia sobre como comprar Cassava Sciences ações na Kraken a partir de US$ 10.